+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Post European Society for Medical Oncology (ESMO) Report

  • ID: 4850753
  • Report
  • October 2019
  • Region: Europe
  • 117 Pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for non-small lung cancer and Kisqali for breast cancer.

This post-meeting report features summaries of a few key topics along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.

Note: Product cover images may vary from those shown
2 of 2

Summary

About the Author

Disclaimer

Drug Abstracts

Biliary Tract Cancer
Pemigatinib for Biliary Tract Cancer (INCY, Phase III)
Tibsovo for Biliary Tract Cancer (AGIO, Phase III)

Bladder Cancer
Enfortumab Vedotin for Bladder Cancer (Astellas, BLA)
Sacituzumab Govitecan for Bladder Cancer (IMMU, Phase II)
Tecentriq for Bladder Cancer (RHHBY, Approved)

Breast Cancer
G1T48 for Breast Cancer (G1 Therapeutics, Phase I)
Keytruda for Breast Cancer (MRK, Phase III)
Keytruda for Breast Cancer (MRK, Phase III)
Kisquali for Breast Cancer (NVS, Approved)
Trilaciclib for Breast Cancer (G1 Therapeutics, Phase II)
Verzenio for Breast Cancer (LLY, Approved)

Colorectal Cancer
AMG 510 for Colorectal Cancer (CRC) (AMGN, Phase I)
Braftovi for Colorectal Cancer (CRC) (PFE, Phase III)
Tucatinib for Colorectal Cancer (CRC) (PFE, Phase III)

Esophageal Cancer
Opdivo for Esophageal Cancer (BMY, Phase III)

Gastric Cancer
Margetuximab for Gastric Cancer (MGNX, Phase II)

Head and Neck Cancer
Debio 1143 for Head and Neck Cancer (Debiopharm, Phase II)
Monalizumab for Head and Neck Cancer (AZN, Phase II)

Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)
Opdivo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (BMY, Approved)
Tecentriq for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (RHHBY, Phase III)

Non-Small Cell Lung Cancer (NSCLC)
AMG 510 for Non-Small Cell Lung Cancer (NSCLC) (AMGN, Phase I)
Opdivo for Non-Small Cell Lung Cancer (NSCLC) (BMY, Approved)
Tagrisso for Non-Small Cell Lung Cancer (NSCLC) (AZN, Approved)
Tecentriq for Non-Small Cell Lung Cancer (NSCLC) (RHHBY, Approved)

Ovarian Cancer
AVB-500 for Ovarian Cancer (ARAV, Phase II)
Lynparza for Ovarian Cancer (AZN, Approved)
M6620 for Ovarian Cancer (MKGAY, Phase II)
Mirvetuximab Soravtansine for Ovarian Cancer (IMGN, Phase III)
Veliparib for Ovarian Cancer (ABBV, Phase III)
Zejula for Ovarian Cancer (GSK, Approved)

Prostate Cancer
Erleada for Prostate Cancer (JNJ, Approved)
Lynparza for Prostate Cancer (AZN, Phase III)
Rubraca for Prostate Cancer (CLVS, Phase III)
SM-88 for Prostate Cancer (TYME, Phase II)
Zejula for Prostate Cancer (GSK, Phase III)

Renal Cell Cancer (RCC)
Mavorixafor for Renal Cell Cancer (RCC) (XFOR, Phase II)
MK-6482 for Renal Cell Cancer (RCC) (MRK, Phase II)
Tivopath (Oncology) for Renal Cell Cancer (RCC) (AVEO, Phase III)

Solid Tumors
ALRN-6924 for Solid Tumors (ALRN, Phase II)

Thyroid Cancer
Selpercatinib for Thyroid Cancer (LLY, Phase II)

Note: Product cover images may vary from those shown
Adroll
adroll